STRATEGY
Clearer choices
We help leadership teams clarify market priorities, entry logic, product focus and resource allocation before major commitments are made.
WEXACT GLOBAL GROWTH
WExAct helps selected Chinese MedTech companies move beyond opportunistic export sales and build more structured international growth — through strategic clarity, market entry discipline, channel development and trusted regional collaboration.
MARKET SHIFT
For many Chinese MedTech companies, international growth began with export orders, trade-show leads and distributor relationships built one market at a time.
That model can create early momentum, but it rarely builds a repeatable international business. As markets become more regulated, competitive and channel-driven, growth increasingly depends on structured choices: where to focus, how to enter, who to work with and how to manage progress over time.
The next stage belongs to companies that can turn product strength into market traction — and market traction into sustainable international capability.
OUR ROLE
We sit between the boardroom and the field. We help leadership teams set direction, then run the program with them through the first phase of international results.
STRATEGY
We help leadership teams clarify market priorities, entry logic, product focus and resource allocation before major commitments are made.
EXECUTION
We stay close to the work after the strategy is defined, helping teams maintain focus, rhythm and accountability as international initiatives move forward.
NETWORK
We work with trusted regional collaborators through real project experience, not overstated coverage claims or generic partner databases.
GLOBAL GROWTH SYSTEM
Six modules. Used in different combinations depending on the company's stage, market and capability gaps.
Understanding market structure, customer behavior, competitive dynamics and practical entry barriers.
Defining where the company can credibly compete and how its products should be positioned.
Translating product strength into market-specific value propositions and adoption logic.
Designing market-appropriate routes to customers through distributors, direct engagement or hybrid models.
Supporting the transition from market plan to meaningful commercial conversations and partner engagement.
Building the management rhythm and review discipline needed to sustain international growth.
WHO WE SERVE
Most of our work is with Chinese MedTech companies. Each engagement opens connections to partners, experts and capital — which compounds the value of the network for everyone.
For companies with real product substance and the ambition to build a more repeatable international business.
How we work with companies → — 02For distributors, commercial partners and business bridges seeking qualified Chinese MedTech collaboration.
How we work with partners → — 03For regional experts who want to contribute expertise to real client work and longer-term collaboration.
Tell us about your work → — 04For investors and strategic capital seeking a grounded view of Chinese MedTech international growth potential.
Speak with us →SELECTED PARTNERS
WExAct is building a selective collaboration network across key regions. We do not claim coverage we have not earned. Our regional relationships grow through active work, defined collaboration and long-term professional trust. The network grows one project at a time.
Explore the network →FIELD NOTES
We publish practical perspectives from international growth work — not generic industry commentary.
AI has transformed consumer applications at speed, but in healthcare the pace is deliberately slower—and for good reason. The barriers are structural: clinical evidence requirements, multi-stakeholder decision chains, regulatory approval in every target market, and fragmented reimbursement systems that vary dramatically by country. Understanding these dynamics explains why IBM Watson failed, why many well-funded AI health companies still lack a scalable revenue model, and what Chinese MedTech companies must think through before committing to an AI-led international expansion.
Country MarketChina's visa-free access to Brazil, effective May 2026, has renewed interest in the country among Chinese MedTech exporters. The market's appeal is grounded in real fundamentals: top-ten global scale, a public health system covering 215 million people, and increasingly centralized private hospital procurement. Yet the barriers are equally real—ANVISA registration cannot be held directly by foreign entities, combined import tax burdens can reach 60%, and public tender participation requires deep local compliance infrastructure. This article provides a structured assessment of Brazil's market architecture, entry barriers, competitive dynamics, and the conditions under which serious market commitment makes strategic sense.
Market InsightsAfter years of working with Chinese MedTech companies on international expansion, a pattern emerges consistently: companies spend three to four years and significant resources in a market, only to discover that its total addressable size was always limited, or that competitors had already locked in the key channels long before entry. This is not a sales execution problem—it is the consequence of a decision that was never made rigorously in the first place. Systematic target market selection is the foundation of any credible international strategy, and the single decision most likely to determine whether overseas investment compounds or simply accumulates as sunk cost.
TALK TO US
